Join our study for a new treatment for a type of blood cancer, Acute Myeloid Leukemia (AML) with a specific mutation called FLT3. We are looking for older adults who have recently been diagnosed and who may not be fit for intense treatments. The study involves testing a combination of medicines to see if they help. This study looks at two ways to treat AML. We will compare the usual treatment with Azacitidine and Venetoclax to adding a new medicine called Gilteritinib to them.
Thank you for your interest, but this study will start enrolling soon.
United States (Nationwide)
Joshua Zeidner
Lineberger Comprehensive Cancer Center
Clinical or Medical
Interventional
Cancer (Leukemia)
25-0948
Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.
Questions?
